Form 4: Catalyst Pharmaceuticals Executive Sundaram Reports Stock Transactions
SEC Form 4 Filing
Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On December 27, 2024, Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, had restricted stock units vest, resulting in the acquisition of 6,667 shares.
- 2,345 shares were withheld by Catalyst Pharmaceuticals to satisfy applicable withholding taxes.
- Following these transactions, Sundaram directly owns 34,303 shares of Catalyst Pharmaceuticals common stock.
- The reported transactions relate to the vesting of restricted stock units granted to Sundaram, which vest in three equal tranches on December 27, 2023, December 27, 2024, and December 27, 2025.
- The second tranche of shares was delivered on December 27, 2024.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the stock ownership of key personnel.
Stakeholder Impact
- The vesting of restricted stock units and subsequent tax withholding has a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 12/27/2023 | First tranche of restricted stock units vested. |
| 12/27/2024 | Second tranche of restricted stock units vested; shares delivered and taxes withheld. |
| 12/27/2025 | Final tranche of restricted stock units scheduled to vest. |
| 12/31/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.